SCHEMBL20202546

SCHEMBL20202546

CC(C)(C)OC(=O)N/N=C(/c1ccccc1)C1CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.48
NPC1 O15118 4/20 0.48
KMT2A Q03164 4/20 0.48
HTT P42858 2/20 0.48
MEN1 O00255 2/20 0.48
MAPT P10636 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KDM1A O60341 1/20 0.41
MAOB P27338 1/20 0.41
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
ACACB O00763 1/20 0.39
ACACA Q13085 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CTSK P43235 1/20 0.39
MIF P14174 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20185490 0.86 RAB9A (0.42) RAB9ANPC1KMT2AHTTMEN1
SCHEMBL22750830 0.79 RAB9A (0.55) RAB9ANPC1KMT2AHTTMEN1
SCHEMBL2599809 0.75 LMNA (0.42) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL5147809 0.75 KDM4E (0.52) KMT2AMEN1KDM4EPKM
SCHEMBL3842085 0.74 MAPT (0.50) RAB9ANPC1KMT2AHTTMEN1
SCHEMBL20583674 0.72 NPC1 (0.43) RAB9ANPC1KMT2AHTTMEN1
SCHEMBL20583676 0.72 NPC1 (0.43) RAB9ANPC1KMT2AHTTMEN1
SCHEMBL24130820 0.72 KDM1A (0.58) NPC1KMT2AMEN1KDM1AMAOB
SCHEMBL20185549 0.71 RAB9A (0.46) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL14077434 0.70 SMN1; SMN2 (0.69) RAB9ANPC1KMT2AHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174037-B2 Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2019-01-08 US disclosed
US-20180148453-A1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-31 US disclosed
US-20180148453-A1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148453-A1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS PDE12, PDE2A, PDE4D RAB9A 700/4885NPC1 3559/4885KMT2A 1496/4885
US-10174037-B2 Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors PDE12, PDE2A, PDE4D RAB9A 700/4885NPC1 3559/4885KMT2A 1496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.